Clinical Potential of Anti-inflammatory Effects of Faecalibacterium prausnitzii and Butyrate in Inflammatory Bowel Disease

Inflamm Bowel Dis. 2019 Mar 14;25(4):e40-e41. doi: 10.1093/ibd/izy258.

Authors

Stanislav Sitkin^{1

2}, Juris Pokrotnieks^{3

4}

Affiliations

¹ Department of Internal Diseases, Gastroenterology and Dietetics, North-Western State Medical University named after I.I. Mechnikov, St. Petersburg, Russia.
² Research Department, Elpis SIA, Riga, Latvia.
³ Department of Internal Diseases, Rīga Stradiņš University, Riga, Latvia.
⁴ Centre of Gastroenterology, Hepatology and Nutrition, Pauls Stradiņš Clinical University Hospital, Riga, Latvia.

PMID: 30085080
DOI: 10.1093/ibd/izy258

No abstract available

Publication types

Letter
Comment

MeSH terms

Anti-Inflammatory Agents
Butyrates
Colitis*
Colorectal Neoplasms*
Faecalibacterium prausnitzii
Histone Deacetylase 1
Humans
Inflammatory Bowel Diseases*
T-Lymphocytes, Regulatory

Substances

Anti-Inflammatory Agents
Butyrates
Histone Deacetylase 1